In amyotrophic lateral sclerosis (ALS) and animal models of ALS, including SOD1-G93A mice, disassembly of the neuromuscular synapse precedes motor neuron loss and is sufficient to cause a decline in motor function that culminates in lethal respiratory paralysis. We treated SOD1-G93A mice with an agonist antibody to MuSK, a receptor tyrosine kinase essential for maintaining neuromuscular synapses, to determine whether increasing muscle retrograde signaling would slow nerve terminal detachment from muscle. The agonist antibody, delivered after disease onset, slowed muscle denervation, promoting motor neuron survival, improving motor system output, and extending the lifespan of SOD1-G93A mice. These findings suggest a novel therapeutic strategy for ALS, using an antibody format with clinical precedence, which targets a pathway essential for maintaining attachment of nerve terminals to muscle.
- Steven J Burden
- Steven J Burden
- George Z Mentis
- Sarah Cantor
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Animal experimentation: All procedures were approved and mice were maintained according to Institutional Animal Use and Care Committee (IACUC protocol number 160425) guidelines at NYU Medical School.
- Jonathan Glass, Emory University, United States
- Received: December 14, 2017
- Accepted: February 2, 2018
- Accepted Manuscript published: February 20, 2018 (version 1)
- Accepted Manuscript updated: February 20, 2018 (version 2)
- Accepted Manuscript updated: February 22, 2018 (version 3)
- Version of Record published: March 5, 2018 (version 4)
- Version of Record updated: June 7, 2018 (version 5)
© 2018, Cantor et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.